BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.

Autor: Hutter-Saunders JA; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, 985880 Nebraska Medical Center (DRC I 8008), Omaha, NE 68198-5880, USA., Kosloski LM, McMillan JM, Yotam N, Rinat T, Mosley RL, Gendelman HE
Jazyk: angličtina
Zdroj: Neuroscience [Neuroscience] 2011 Apr 28; Vol. 180, pp. 293-304. Date of Electronic Publication: 2011 Feb 12.
DOI: 10.1016/j.neuroscience.2011.02.015
Abstrakt: The therapeutic potential of BL-1023, a chemical combination of L-3,4-dihydroxyphenylalanine (L-DOPA) and gamma-aminobutyric acid (GABA), was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated mice. Such animals exhibit nigrostriatal degeneration, characteristic of human Parkinson's disease. Drug was administered during and after the development of MPTP-induced nigrostriatal lesions followed by measures of motor function and behavior, surviving nigrostriatal dopaminergic neurons and termini, and striatal dopamine levels. When administered after lesion development, BL-1023 improved motor function of MPTP-mice as measured by rotarod, total floor and vertical plane movements, and stereotypic movements in open field activity tests compared to MPTP-mice without treatment. This also paralleled modest nigral dopaminergic neuronal protection. Such significant improvements in motor function, behaviors, and dopaminergic neuronal numbers were not seen when BL-1023 was administered during MPTP-induced lesion development. The data demonstrate select abilities of BL-1023 to increase dopaminergic neuronal survival and improve motor function in MPTP-mice.
(Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: